| Virology Journal | |
| Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches | |
| Amine A Kamen1  Olivier Henry1  Alexandre Lennaertz1  Emma Petiot2  Christine M Thompson1  | |
| [1] École Polytechnique de Montréal, C.P. 6079, succ. Centre-ville, Montréal, Québec H3C 3A7, Canada;National Research Council Canada, Vaccine Program – Human Health therapeutics Portfolio, 6100 Royalmount Avenue, Montreal, Québec H4P 2R2, Canada | |
| 关键词: Vaccines; Total particles; Process Analytical Technologies; Quantification; Influenza virus-like particles (VLPs); | |
| Others : 1150439 DOI : 10.1186/1743-422X-10-141 |
|
| received in 2013-01-21, accepted in 2013-04-29, 发布年份 2013 | |
PDF
|
|
【 摘 要 】
Influenza virus-like particle vaccines are one of the most promising ways to respond to the threat of future influenza pandemics. VLPs are composed of viral antigens but lack nucleic acids making them non-infectious which limit the risk of recombination with wild-type strains. By taking advantage of the advancements in cell culture technologies, the process from strain identification to manufacturing has the potential to be completed rapidly and easily at large scales. After closely reviewing the current research done on influenza VLPs, it is evident that the development of quantification methods has been consistently overlooked. VLP quantification at all stages of the production process has been left to rely on current influenza quantification methods (i.e. Hemagglutination assay (HA), Single Radial Immunodiffusion assay (SRID), NA enzymatic activity assays, Western blot, Electron Microscopy). These are analytical methods developed decades ago for influenza virions and final bulk influenza vaccines. Although these methods are time-consuming and cumbersome they have been sufficient for the characterization of final purified material. Nevertheless, these analytical methods are impractical for in-line process monitoring because VLP concentration in crude samples generally falls out of the range of detection for these methods. This consequently impedes the development of robust influenza-VLP production and purification processes. Thus, development of functional process analytical techniques, applicable at every stage during production, that are compatible with different production platforms is in great need to assess, optimize and exploit the full potential of novel manufacturing platforms.
【 授权许可】
2013 Thompson et al.; licensee BioMed Central Ltd.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 20150405183824578.pdf | 289KB |
【 参考文献 】
- [1]Kalbfuss B, Knöchlein A, Kröber T, Reichl U: Monitoring influenza virus content in vaccine production: Precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 2008, 36:145-161.
- [2]Influenza (Seasonal 2009) Factshee. [http://www.who.int/mediacentre/factsheets/fs211/en/ webcite]
- [3]Cohen J: Out of Mexico ? Scientists Ponder Swine Flu’ s Origins. Science 2009, 324:700-703.
- [4]Michaelis M, Doerr HW, Cinatl J: Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. Med Microbiol Immunol 2009, 198:175-183.
- [5]Gerdil C: The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
- [6]WHO: Department of Immunization, Vaccines and Biologicals. Geneva: Global Pandemic Influenza Action Plan to Increase Vaccine Supply; 2006.
- [7]FDA News Release: FDA approves first seasonal influenza vaccine manufactured using cell culture technology. 2012. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm328982.htm webcite
- [8]FDA News Release: FDA approves new seasonal influenza vaccine made using novel technology. 2013. [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm webcite]
- [9]Chua JV, Chen WH: Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks. Critical Care (London, England) 2010, 14:218. BioMed Central Full Text
- [10]Kang S-M, Yoo D-G, Lipatov AS, Song J-M, Davis CT, Quan F-S, Chen L-M, Donis RO, Compans RW: Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4:e4667.
- [11]Haynes JR: Influenza virus-like particle vaccines. Expet Rev Vaccine 2009, 8:435-445.
- [12]Wu C-Y, Yeh Y-C, Yang Y-C, Chou C, Liu M-T, Wu H-S, Chan J-T, Hsiao P-W: Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 2010, 5:e9784.
- [13]Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G: Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
- [14]Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu K, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, Girard M, He R, Li X: Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 2010, 28:5774-5784.
- [15]Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ: A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS One 2011, 6:e26335.
- [16]Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R: Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 2010, 45:226-234.
- [17]Tang X-C, Lu H-R, Ross TM: Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol 2011, 24:311-319.
- [18]D’Aoust M-A, Couture MM-J, Charland N, Trépanier S, Landry N, Ors F, Vézina L-P: The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010, 8:607-619.
- [19]Latham T, Galarza JM: Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins. Society 2001, 75:6154-6165.
- [20]Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser J, Tumpey TM: Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 2011, 29:5911-5918.
- [21]Quan F-S, Huang C, Compans RW, Kang S-M: Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007, 81:3514-3524.
- [22]Bright R, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM: Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878.
- [23]Mahmood K, Bright R, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM: H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26:5393-5399.
- [24]Lai JCC, Chan WWL, Kien FF, Nicholls JM, Peiris JSM, Garcia J-M: Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J Gen Virol 2010, 91(Pt 9):2022-2030.
- [25]Chen BJ, Leser GP, Morita E, Lamb R: Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007, 81:7111-7123.
- [26]Szécsi J, Gabriel G, Edfeldt G, Michelet M, Klenk HD, Cosset F-L: DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J Infect Dis 2009, 200:181-190.
- [27]Szécsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, Klenk H-D, Klatzmann D, Volchkov V, Cosset F-L: Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 2006, 3:70. BioMed Central Full Text
- [28]Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP: Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine 2012, 30:3413-3422.
- [29]D’Aoust M-A, Lavoie P-O, Couture MM-J, Trépanier S, Guay J-M, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina L-P: Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008, 6:930-940.
- [30]Wu C-Y, Yeh Y-C, Chan J-T, Yang Y-C, Yang J-R, Liu M-T, Wu H-S, Hsiao P-W: A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One 2012, 7:e42363.
- [31]Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang S-M: A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008, 26:3352-3361.
- [32]Galarza JM, Latham T, Cupo A: Protection against a Lethal Influenza Virus Challenge. Viral Immunol 2005, 18:244-251.
- [33]Kang S-M, Song J-M, Quan F-S, Compans RW: Influenza vaccines based on virus-like particles. Virus Res 2009, 143:140-146.
- [34]Donald HB, Isaacs A: Counts of influenza virus particles. J Gen Microbiol 1954, 10:457-464.
- [35]Nayak DP, Reichl U: Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus. J Virol Meth 2004, 122:9-15.
- [36]Schild GC, Wood JM, Newman RW: A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 1975, 52:223-231.
- [37]Hirst BYGK: The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med 1942, 75:49-64.
- [38]KJ S, Balish A, Katz J: Influenza: Propagation, Quantification and Storage. In Current Protocols in Microbiology. John Wiley & Sons; 2006:1-22.
- [39]Creskey MC, Li C, Wang J, Girard M, Lorbetskie B, Gravel C, Farnsworth A, Li X, Smith DGS, Cyr TD: Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Vaccine 2012, 30:4762-4770.
- [40]Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, Donis RO, Barr JR: Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008, 26:2510-2520.
- [41]Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, Li X, Girard M: Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011, 29:3377-3389.
- [42]Chun S, Li C, Van Domselaar G, Wang J, Farnsworth A, Cui X, Rode H, Cyr TD, He R, Li X: Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 2008, 26:6068-6076.
- [43]Nilsson CE, Abbas S, Bennemo M, Larsson a, Hämäläinen MD, Frostell-Karlsson a: A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010, 28:759-766.
- [44]Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, Bethell RC: Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000, 280:291-300.
- [45]Li C, Jaentschke B, Song Y, Wang J, Cyr TD, Van Domselaar G, He R, Li X: A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc 2010, 5:14-19.
- [46]Driskell JD, Jones Ca, Tompkins SM, Tripp Ra: One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. Analyst 2011, 136:3083-3090.
- [47]Stepp PC, Ranno KA, Dawson ED, Rowlen KL, Ferris MM: Comparing H1N1 Virus quantification with unique flow cytometer and quantitative PCR. Bioprocess I 2011, 9:50-56.
- [48]McEvoy M, Razinkov V, Wei Z, Casas-Finet JR, Tous GI, Schenerman M: Improved particle counting and size distribution determination of aggregated virus populations by asymmetric flow field-flow fractionation and multiangle light scattering techniques. Biotechnol Prog 2011, 27:547-554.
- [49]Pease LF, Lipin DI, Tsai D-H, Zachariah MR, Lua LHL, Tarlov MJ, Middelberg APJ: Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol Bioeng 2009, 102:845-855.
- [50]Wei Z, McEvoy M, Razinkov V, Polozova A, Li E, Casas-Finet J, Tous GI, Balu P, Pan A, Mehta H, Schenerman M: Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity. J Virol Meth 2007, 144:122-132.
- [51]Pincus S, Boddapati S, Li J, Sadowski T, Pincus BS: Release and stability testing programs for a novel virus-like particle vaccine. Bio Pharm Int 2010, 26-34.
- [52]Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina L-P: Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5:e15559.
- [53]Kapteyn JC, Porre AM, De Rond EJP, Hessels WB, Tijms M, Kessen H, Slotboom AME, Oerlemans M, Smit D, Van der Linden J, Schoen P, Thus JLG: HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009, 27:1468-1477.
- [54]Wood J, Dunleavy U, Newman R, Riley A, Robertson J, Minor P: The influence of the host cell on standardisation of influenza vaccine potency. Dev Biol Stand 1999, 98:183-188.
- [55]Wood J, Schild G, Newman R, Seagroatt V: An improved single-radial-immunodifusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977, 5:237-247.
- [56]Apostolov K, Fishman B: Purification and concentration of influenza virus by auto-aggregation. Nature 1967, 1287-1288.
- [57]Petiot E, Jacob D, Lanthier S, Lohr V, Ansorge S, Kamen A: Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol 2011, 11:84. BioMed Central Full Text
- [58]Kalbfuss B, Wolff M, Morenweiser R, Reichl U: Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol Bioeng 2007, 96:932-944.
- [59]Wen Z, Ye L, Gao Y, Pan L, Dong K, Bu Z, Compans RW, Yang C: Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res 2009, 84:215-224.
- [60]Isaacs A, Donald HB: Particle counts of haemagglutinating viruses. J Gen Microbiol 1955, 12:241-247.
- [61]Krammer F, Nakowitsch S, Messner P, Palmberger D, Ferko B, Grabherr R: Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol J 2010, 5:17-23.
- [62]Chang GR-L, Lai S-Y, Chang P-C, Wang M-Y: Production of immunogenic one-component avian H7-subtype influenza virus-like particles. Process Biochem 2011, 46:1292-1298.
- [63]Margine I, Martinez-Gil L, Chou Y, Krammer F: Residual Baculovirus in Insect Cell-Derived Influenza Virus-Like Particle Preparations Enhances Immunogenicity. PLoS One 2012, 7:e51559.
- [64]Tang X-C, Lu H-R, Ross TM: Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine 2010, 28:6821-6831.
- [65]Gavrilov V, Orekov T, Alabanza C, Porika U, Jiang H, Connolly K, Pincus S: Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J Virol Meth 2011, 173:364-373.
- [66]Kapteyn JC, Saidi MD, Dijkstra R, Kars C, Tjon JCMS-K, Weverling GJ, De Vocht ML, Kompier R, Van Montfort B, Guichoux J-Y, Goudsmit J, Lagerwerf FM: Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine 2006, 24:3137-3144.
- [67]Garcia-Cañas V, Lorbetskie B, Girard M: Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. J Chromatogr A 2006, 1123:225-232.
- [68]Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Van Domselaar G: Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays. J Vis Exp 2011, 50:1-7.
- [69]GE Healthcare: Biacore ™ biosensor assays for quantitation of influenza virus and HCP. Uppsala: GE Healthcare; 2010.
- [70]Mandenius C-F, Wang R, Aldén A, Bergström G, Thébault S, Lutsch C, Ohlson S: Monitoring of influenza virus hemagglutinin in process samples using weak affinity ligands and surface plasmon resonance. Anal Chim Acta 2008, 623:66-75.
- [71]Stoffel CL, Kathy RF, Rowlen KL: Design and characterization of a compact dual channel virus counter. Cytometry Part A: J Int Soc Anal Cytol 2005, 65:140-147.
- [72]Ferris MM, Stepp PC, Ranno KA, Mahmoud W, Jarvis J, Cox MMJ, Christensen K, Votaw H, Dean P, Rowlen KL: Evaluation of the Virus counter for rapid baculovirus quantitation. J Virol Meth 2012, 171:111-116.
- [73]Block O, Mitra A, Novotny L, Dykes C: A rapid label-free method for quantitation of human immunodeficiency virus type-1 particles by nanospectroscopy. J Virol Meth 2012, 182:70-75.
- [74]Citkowicz A, Petry H, Harkins RN, Ast O, Cashion L, Goldmann C, Bringmann P, Plummer K, Larsen BR: Characterization of virus-like particle assembly for DNA delivery using asymmetrical flow field-flow fractionation and light scattering. Anal Biochem 2008, 376:163-172.
- [75]Saifer Mark GP, Williams DL: Quantification of Viruses by Light Scattering. U.S Patent US6 2003, 544:770. B2
- [76]Medley CD, Smith JE, Tang Z, Wu Y, Bamrungsap S, Tan W: Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Anal Chem 2008, 80:1067-1072.
- [77]Ling J, Huang CZ, Li YF, Zhang L, Chen LQ, Zhen SJ: Light-scattering signals from nanoparticles in biochemical assay, pharmaceutical analysis and biological imaging. TrAC Trends Anal Chem 2009, 28:447-453.
- [78]Jans H, Liu X, Austin L, Maes G, Huo Q: Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies. Anal Chem 2009, 81:9425-9432.
- [79]Pease LF: Physical analysis of virus particles using electrospray differential mobility analysis. Trends Biotechnol 2012, 30:216-224.
- [80]Guha S, Pease LF, Brorson K, Tarlov MJ, Zachariah MR: Evaluation of electrospray differential mobility analysis for virus particle analysis: potential applications for biomanufacturing. J Virol Meth 2011, 178:201-208.
PDF